HOME ·

03933.HK

UNITED LAB (03933.HK): Semaglutide Weight Management Application Accepted
Tags：
UNITED LAB03933.HKNew Drug Application
2026-11-05
UNITED LAB (03933.HK): semaglutide weight-management filing accepted
Tags：
UNITED LAB03933.HK
2026-11-04
United Lab(3933.HK) gets US$9M second milestone from Novo for UBT251
Tags：
UNITED LAB03933.HKNovo Nordisk
2026-09-25
UNITED LAB (03933.HK): NMPA Accepts Filing for IDegLira; First Chinese Biosimilar Applicant
Tags：
NewTimeSpaceUNITED LAB03933.HK
2026-09-24
UNITED LAB (03933.HK): UBT251 injection completes first participant dosing in Phase III clinical study for type 2 diabetes in China
Tags：
UNITED LAB03933.HKR&D Progress
2026-09-07
The United Laboratories International (03933.HK): UBT48128 Tablets Obtain US FDA Clinical Trial Approval
Tags：
The United Laboratories International03933.HK
2026-08-11
UNITED LAB (03933.HK): Receives US$13.5 Million Milestone Payment from Novo Nordisk for UBT251
Tags：
UNITED LAB03933.HKexclusive licence agreementNovo Nordisk
2026-07-16
United Laboratories (03933.HK): New Specification of Sodium Hyaluronate Eye Drops Approved for Marketing
Tags：
United Laboratories03933.HK
2026-07-14
UNITED LAB(03933.HK): Tadalafil Tablets Approved for Marketing to Expand Layout in Men's Health Sector
Tags：
UNITED LAB03933.HKnew drug launch
2026-07-02
UNITED LAB(03933.HK): TUL321 Capsule Granted Implied Approval for Clinical Trials of New Drug in China
Tags：
UNITED LAB03933.HKClinical Trial
2026-06-11